“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Primary Mucoepidermoid Carcinoma of the Esophagus

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

The Case of the Missed Chest Radiograph: Bilateral Mammary Gland Metastases Mimicking Multifocal Primary Breast Cancer as the Initial Manifestation of.

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung Zhigang.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Sclerosing Pneumocytoma with Lymph Node Metastasis

Spontaneous regression of small cell lung cancer

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report Kazutaka Fujita, MD, Yuko.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma Kazuhisa Nakashima, MD, Tateaki Naito, MD, Shota Omori, MD, Shusuke Yoshikawa,

An Unusual Presentation of Malignant Pleural Mesothelioma

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor Sofia Ghani, MD, Arpita Desai, MD, Saraswati Pokharel, MD, Todd.

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Primary Mucoepidermoid Carcinoma of the Esophagus

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Multiple Pulmonary Chondroid Hamartoma

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Thymic and Mediastinal Lymph Node Metastasis of Colon Cancer

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Multimodality Therapy for Large Cell Neuroendocrine Carcinoma of the Thymus Naoko Ose, MD, Masayoshi Inoue, MD, Eiichi Morii, MD, Yasushi Shintani, MD,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

Nivolumab-Induced Granulomatous Inflammation of the Pleura

It’s All in the “Swerve of the Curve”

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

A Rare Case of Endobronchial Amelanotic Melanoma

Giant Desmoid Tumor of the Chest Wall

Extended Resections for Thymic Malignancies

S-1 Treatment for Chemorefractory Thymic Carcinoma

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi, MD, Esteban C. Gabazza, MD, Yasushi Yatabe, MD, Osamu Taguchi, MD, Nobuyuki Yamamoto, MD Journal of Thoracic Oncology Volume 11, Issue 10, Pages e117-e119 (October 2016) DOI: 10.1016/j.jtho.2016.05.002 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Computed tomography scan showing pulmonary and lymph node metastases surrounding the head of the pancreas. Enlargement of lymph metastases surrounding the head of the pancreas on day 7 and shrinkage of pulmonary and lymph metastases on day 64 after induction therapy with nivolumab. Journal of Thoracic Oncology 2016 11, e117-e119DOI: (10.1016/j.jtho.2016.05.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Hematoxylin and eosin (HE) staining and immunohistochemical analysis of programmed death ligand 1 (PD-L1). (A) HE staining demonstrated pleomorphic carcinoma with giant cells. (B) Immunohistochemical analysis showed positive immune reactivity for PD-L1 performed using the anti–PD-L1 clone E1L3N (Cell Signaling Technology, Danvers, MA). (C) Tumor-infiltrating lymphocytes can be also recognized in the tumor (arrow) (HE staining; ×400 magnification). Journal of Thoracic Oncology 2016 11, e117-e119DOI: (10.1016/j.jtho.2016.05.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions